Experimental HIV Drugs
Experimental HIV Drugs
FDA Advisors Favor Approval of 4-in-1 Elvitegravir Quad Pill for HIV
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 11 May 2012 00:00
- Written by Liz Highleyman
On May 11, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended approval of Gilead Sciences' 4-in-1 once-daily single-tablet antiretroviral regimen known as the Quad. A final decision in expected by late summer.
Novel HIV Integrase Inhibitor Dolutegravir Matches Raltegravir in Phase 3 Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 03 April 2012 00:00
- Written by Press Release
ViiV Healthcare and Japan's Shionogi announced this week that its experimental integrase inhibitor dolutegravir (formerly S/GSK1349572) worked as well as the sole approved integrase inhibitor, raltegravir (Isentress), for people with HIV starting antiretroviral treatment for the first time.
CROI 2012: 4-in-1 Elvitegravir Quad Pill Matches Efavirenz and Atazanavir Combos
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 13 March 2012 00:00
- Written by Liz Highleyman
The Quad single-tablet regimen, an all-in-one pill containing the experimental integrase inhibitor elvitegravir plus 2 other antiretroviral drugs and a novel boosting agent, was as effective as the widely used Atripla combination but with fewer neuropsychiatric side-effects, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle. In a companion study the Quad also matched boosted atazanavir (Reyataz).
Coverage of the 2012 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Friday, 16 March 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com's complete coverage of the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), March 5-8, 2012.
Featuring new HIV drugs, HIV cure research, biomedical prevention, HIV-related conditions and complications, basic science, hepatitis C, and HIV/HCV coinfection.
HIVandHepatitis.com CROI 2012 section
3/16/12
CROI 2012: New Integrase Inhibitor Dolutegravir Still Potent and Well-Tolerated at 96 Weeks
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 09 March 2012 00:00
- Written by Liz Highleyman
The next-generation integrase inhibitor dolutegravir maintains viral suppression and remains safe after 2 years of use, according to a small study presented Wednesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
Web Design and Development by